Wayne A. I. Frederick, a surgical oncologist and former president of Howard University, will step in as interim chief executive officer of the American Cancer Society, effective Nov. 2.
A new first-line treatment involving the PD-1 inhibitor nivolumab for advanced-stage classic Hodgkin lymphoma could soon make its way into clinics.
If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.
As we come within a stone’s throw of Nov. 5, we can’t help but wonder if and how the election outcome will impact health care policy, and cancer policy in particular.
Two former directors and the current director of the UChicago Medicine Comprehensive Cancer Center appeared in a special episode of the Cancer Luminaries podcast. This series was launched by UCCCC to mark its 50th year as an NCI-designated cancer center.
Hispanic and Latino people comprise nearly 20% of the U.S. population, but less than 6% of physicians nationwide identify as Hispanic.
Hurricane Milton via satellite on Wednesday. Source: NOAA/NESDISSTAR GOES-EastMilton—the second hurricane in as many weeks—ripped through America’s southeast, causing severe flooding, washing away bridges, knocking out power and water supply.
In 2004, doctors told my husband Mike there was nothing more they could do—the pancreatic cancer he was diagnosed with would soon take his life.
Less Radical tells the story of surgeon-scientist Bernie Fisher, who revolutionized breast cancer treatment and transformed the way we understand cancer.
The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.
